Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
- Author:
Kwang Hyun CHUNG
1
;
Ji Kon RYU
;
Jun Hyuk SON
;
Jae Woo LEE
;
Dong Kee JANG
;
Sang Hyub LEE
;
Yong Tae KIM
Author Information
- Publication Type:Original Article
- Keywords: Carcinoma, pancreatic ductal; Treatment outcome; Capecitabine; Oxaliplatin; Salvage therapy
- MeSH: Adenocarcinoma; Anorexia; Capecitabine*; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Drug Therapy; Drug Therapy, Combination*; Humans; Mortality; Neutropenia; Pancreatic Ducts; Pancreatic Neoplasms*; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Typhlitis; Vomiting
- From:Gut and Liver 2017;11(2):298-305
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Second-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC) that progresses following gemcitabine-based treatment has not been established. This study aimed to investigate the efficacy and safety of second-line combination chemotherapy with capecitabine and oxaliplatin (XELOX) in these patients. METHODS: Between August 2011 and May 2014, all patients who received at least one cycle of XELOX (capecitabine, 1,000 mg/m² twice daily for 14 days; oxaliplatin, 130 mg/m² on day 1 of a 3-week cycle) combination chemotherapy for unresectable or recurrent PDAC were retrospectively recruited. The response was evaluated every 9 weeks, and the tumor response rate, progression-free survival and overall survival, and adverse events were assessed. RESULTS: Sixty-two patients were included; seven patients (11.3%) had a partial tumor response, and 20 patients (32.3%) had stable disease. The median progression-free and overall survival were 88 days (range, 35.1 to 140.9 days) and 158 days (range, 118.1 to 197.9 days), respectively. Patients who remained stable longer with frontline therapy (≥120 days) exhibited significantly longer progression-free and overall survival. The most common grade 3 to 4 adverse events in patients were vomiting (8.1%) and anorexia (6.5%). There was one treatment-related mortality caused by severe neutropenia and typhlitis. CONCLUSIONS: Second-line XELOX combination chemotherapy demonstrated an acceptable response and survival rate in patients with advanced PDAC who had failed gemcitabine-based chemotherapy.
